Plain-English translation of NCT07185165 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new type of imaging scan called flotufolastat F-18 PET/CT to see whether it can accurately detect if prostate cancer has come back after focal therapy — a treatment that targets only the cancerous area rather than the whole prostate. Researchers want to know if this new scan works as well as or better than a biopsy (a tissue sample) at finding any remaining or recurring cancer. This medication highlights cancer cells so doctors can see them on the scan.
After focal therapy for prostate cancer, doctors need a reliable way to know if the treatment worked and whether any cancer remains. Currently, a biopsy is the standard way to check, but it's invasive and uncomfortable. This trial exists to see if the new imaging scan can give doctors the same information without needing to take tissue samples.
You likely qualify if…
You likely don't qualify if…
You would receive an injection of the new medication through your vein, then wait 50 to 100 minutes. Next, you would have a PET/CT scan (a whole-body imaging scan) that takes 20 to 50 minutes. Within three months, you would have a biopsy guided by ultrasound and the scan images. After that, you would have a follow-up visit one month later, and then annual check-ins for up to 10 years.
AI-generated summary from trial data · Jun 24, 2026 · Not medical advice
United States